Project PRESCIENT (Pre- & early cancer screening by analysing cell-free DNA methylome) is a multi-investigator collaboration at the Singapore General Hospital as part of an early cancer detection research programme led by the Cancer Discovery Hub. This project will study blood plasma (or other fluid)-derived cell-free DNA methylome of pre-& early stage cancer of the following tissues: liver, gastrointestinal tract, lungs, breast & blood (lymphoma). Examples of pre-cancer conditions include: liver cirrhosis, non-alcoholic fatty liver disease, chronic smoker’s lungs, inflammatory bowel disease & clonal haematopoiesis of indeterminate potential.
Expected to be launched in Q1 of 2023, The aims of project PRESCIENT are:
To collaborate with clinician researchers across the Singapore General Hospital to investigate the feasibility of using blood plasma (or other fluid)-derived cell-free DNA methylome as pre- & early cancer biomarkers.
To investigate next generation sequencing (NGS) platforms, such as enzyme-mediated methylation-seq (EM-seq), as novel early cancer detection tools.
Programme Director: Dr Ko Tun Kiat
Project Coordinator: Ms Lim Boon Yee
新加坡中央医院的格式部门将成立早期癌症检测研究团队，重点关注五大癌症亚群 - 肝癌，胃肠道癌，肺癌，乳癌，淋巴癌。新加坡国立癌症中心 (Cancer Discovery Hub) 带领的这项提案，目标是针对早期发现和治愈首要癌症，并使用最新的液体活检与精准医疗技术，包括检测甲基化脱氧核糖核酸等技术。